Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

Año: 2022

Publisher: Taylor & Francis Online

Abstract: The aim of this study was to analyze, through a multicriteria decision analysis (MCDA), the potential of bimekizumab for the treatment of moderate-severe psoriasis, compared with placebo, adalimumab, ustekinumab, secukinumab, ixekizumab and risankizumab.

Based on an adaptation of the EVIDEM framework, the final estimated drug values were obtained using an additive linear model combining weights of the drug criteria and scores, according to a multidisciplinary committee of 12 experts.

Under this methodology of increasing use in the healthcare setting, bimekizumab was evaluated as a high value-added drug against the six alternatives analyzed. The drug provides substantial therapeutic benefit and improves patient-reported health outcomes by combining a higher level of clearance, speed and persistence, with a similar safety and tolerability profile.

Keywords: Psoriasis, Moderate-to-Severe, Biologics, Multi-Criteria Decision Analysis, MCDA, bimekizumab.

How to cite: Néboa Zozaya González, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, José Manuel Carrascosa Carrillo, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio García-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de los Ríos Luna, Lluis Puig, Sandra Ros & Álvaro Hidalgo (2022) Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2022.2063842